This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gil, J. Articles by Perucho, M. Search for Related Content PubMed PubMed Citation Articles by Gil, J. Articles by Perucho, M.

Impairment of the Proapoptotic Activity of Bax by Missense Mutations Found in Gastrointestinal Cancers¹

The Burnham Institute, La Jolla, California 92037

We have reported previously that codon 169 of the proapoptotic gene BAX is a mutational hot spot in gastrointestinal cancer. Two different mutations were found in this codon, replacing the wild-type threonine by alanine or methionine. To compare the proapoptotic activity of these Bax mutants with wild-type Bax, we established an ecdysone (muristerone A)-inducible system in cultured human embryonal kidney 293 cells. Addition of muristerone A induced a dose-dependent decrease in the viability of cells transfected with wild-type BAX, but this loss of viability was inhibited in cells transfected with BAX mutants. Furthermore, muristerone A induced morphological changes characteristic of apoptosis, including cell shrinkage, rounding, formation of apoptotic bodies, detachment and nuclear condensation and fragmentation, in cells transfected with wild-type BAX. These hallmarks of apoptosis were clearly diminished in cells transfected with BAX mutants. Mutation of threonine 169 did not affect the binding of Bax to Bax, Bcl-2, or Bcl-X_L. These results demonstrate that missense mutations at codon 169 of BAX are functional because they inhibit its apoptotic activity. This is the first report of the functional significance of missense mutations in BAX, or any other proapoptotic member of the Bcl-2 family, in primary human tumors.

This article has been cited by other articles:

				L L Loro, A C Johannessen, and O K Vintermyr Loss of BCL-2 in the progression of oral cancer is not attributable to mutations J. Clin. Pathol., November 1, 2005; 58(11): 1157 - 1162. [Abstract] [Full Text] [PDF]

				J. Pan, H. Huang, L. Sun, B. Fang, and S.-C. J. Yeung Bcl-2-Associated X Protein Is the Main Mediator of Manumycin A-Induced Apoptosis in Anaplastic Thyroid Cancer Cells J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3583 - 3591. [Abstract] [Full Text] [PDF]

				A. W. Tolcher, J. Kuhn, G. Schwartz, A. Patnaik, L. A. Hammond, I. Thompson, H. Fingert, D. Bushnell, S. Malik, J. Kreisberg, et al. A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer Clin. Cancer Res., August 1, 2004; 10(15): 5048 - 5057. [Abstract] [Full Text] [PDF]

				K. Suzuki, T. Dai, I. Suzuki, Y. Dai, K. Yamashita, and M. Perucho Low Mutation Incidence in Polymorphic Noncoding Short Mononucleotide Repeats in Gastrointestinal Cancer of the Microsatellite Mutator Phenotype Pathway Cancer Res., April 1, 2002; 62(7): 1961 - 1965. [Abstract] [Full Text] [PDF]

				C. M. Knudson, G. M. Johnson, Y. Lin, and S. J. Korsmeyer Bax Accelerates Tumorigenesis in p53-deficient Mice Cancer Res., January 1, 2001; 61(2): 659 - 665. [Abstract] [Full Text]

				S. Kagawa, J. Gu, S. G. Swisher, L. Ji, J. A. Roth, D. Lai, L. C. Stephens, and B. Fang Antitumor Effect of Adenovirus-mediated Bax Gene Transfer on p53-sensitive and p53-resistant Cancer Lines Cancer Res., March 1, 2000; 60(5): 1157 - 1161. [Abstract] [Full Text]

				Y. Ionov, H. Yamamoto, S. Krajewski, J. C. Reed, and M. Perucho Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution PNAS, September 26, 2000; 97(20): 10872 - 10877. [Abstract] [Full Text] [PDF]